Isoniazid preventive treatment in children in two districts of South India: Does practice follow policy?

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 8, 2014, Pages 919-924

  Shivaramakrishna, H R ^a   Frederick, A ^b   Shazia, A ^a   Murali, L ^c   Satyanarayana, S ^d   Nair, S A ^a   Kumar, A M ^d   Moonan, P K ^e  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b Revised National TB Control Programme (RNTCP) District Tuberculosis Unit   (India)

^c RNTCP State Tuberculosis Unit   (India)

^d INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Children; Contact investigation; Isoniazid; Preventive treatment; Tuberculosis

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ARTICLE; CHILD; CHILDHOOD DISEASE; DISEASE COURSE; FEMALE; HEALTH CARE AVAILABILITY; HOME CARE; HUMAN; INCIDENCE; INDIA; INFANT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NEWBORN; PARENTAL ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; PROGRAM EFFICACY; RISK FACTOR; SPUTUM CYTODIAGNOSIS; TREATMENT DURATION; TREATMENT REFUSAL; TUBERCULOSIS CONTROL; ADULT; CONTACT EXAMINATION; CROSS-SECTIONAL STUDY; HEALTH CARE POLICY; MICROBIOLOGY; PUBLIC HEALTH; SPUTUM; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; CONTACT TRACING; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH POLICY; HUMANS; INDIA; INFANT; ISONIAZID; MALE; NATIONAL HEALTH PROGRAMS; SPUTUM; TUBERCULOSIS;

EID: 84904582333     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0072     Document Type: Article

References (23)

1. World Health Organization. Global Tuberculosis Report 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
2. Nelson L J, Wells C D. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 2004; 8: 636-647. (Pubitemid 38625076)
3. Marais B J, Ayles H, Graham S M, Godfrey-Faussett P. Screening and preventive therapy for tuberculosis. Clin Chest Med 2009; 30: 827-846.
4. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. WHO/HTM/TB/2006.371. Geneva, Switzerland: WHO, 2006.
5. Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc Med Thorac 1970; 26: 28- 106.
6. Brummer D L. Preventive therapy of tuberculosis. Annu Rev Med 1974; 25: 115-122.
7. Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update. Respirology 2010; 15: 603-622.
8. Banu Rekha V V, Jagarajamma K, Wares F, Chandrasekaran V, Swaminathan S. Contact screening and chemoprophylaxis in India's Revised Tuberculosis Control Programme: a situational analysis. Int J Tuberc Lung Dis 2009; 13: 1507-1512.
9. Marais B J, van Zyl S, Schaaf H S, van Aardt M, Gie R P, Beyers N. Adherence to isoniazid preventive chemotherapy: a prospective community based study. Arch Dis Child 2006; 91:762- 765.
10. Van Wyk S S, Hamade H, Hesseling A C, Beyers N, Enarson D A, Mandalakas A M. Recording of isoniazid preventive therapy delivery to children: operational challenges. Int J Tuberc Lung Dis 2010; 14: 650-653.
11. Rutherford M E, Ruslami R, Maharani W, et al. Adherence to isoniazid preventive therapy in Indonesian children: A quantitative and qualitative investigation. BMC Res Notes 2012; 5: 7.
12. Gomes V F, Wejse C, Oliveira I, et al. Adherence to isoniazid preventive therapy in children exposed to tuberculosis: a prospective study from Guinea-Bissau. Int J Tuberc Lung Dis 2011; 15: 1637-1643.
13. Garie K T, Yassin M A, Cuevas L E. Lack of adherence to isoniazid chemoprophylaxis in children in contact with adults with tuberculosis in Southern Ethiopia. PLOS ONE 2011; 6: e26452.
14. Aminzadeh Z, Asl R T. A six months follow-up on children less than 6 years old in contact with smear positive tuberculosis patients, Varamin City, Tehran, Iran. Int J Prev Med 2011; 2: 79-81.
15. Le Roux S M, Cotton M F, Golub J E, le Roux D M, Workman L, Zar H J. Adherence to isoniazid prophylaxis among HIVinfected children: a randomized controlled trial comparing two dosing schedules. BMC Med 2009; 7: 67.
16. Central Tuberculosis Division. Technical and Operational Guidelines for Tuberculosis Control, Revised National Tuberculosis Control Programme. Delhi, India: Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, Central Tuberculosis Division, 2005.
17. Pothukuchi M, Nagaraja S B, Kelamane S, et al. Tuberculosis contact screening and isoniazid preventive therapy in a South Indian District: operational issues for programmatic consideration. PLOS ONE 2011; 6: e22500.
18. US Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. Morbid Mortal Wkly Rep MMWR 2011; 60: 1650-1653.
19. Cruz A T, Starke J R. Twice-weekly therapy for children with tuberculosis infection or exposure. Int J Tuberc Lung Dis 2013; 17: 169-174.
20. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman L B. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130: 1712-1717. (Pubitemid 46033423)
21. Page K R, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166: 1863-1870. (Pubitemid 44455169)
22. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149: 689-697.
23. Menzies D, Dion M J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170: 445-449. (Pubitemid 39214621)